The U.S. Government pays Johnson & Johnson (JNJ.N) over $1 billion for 100 million doses of its potential coronavirus vaccine, because it stocks up on vaccine and drugs in a shot to tame the pandemic.
The latest contract is priced at roughly $10 per vaccine dose created by J&J, or around $14.50 per dose, as well as a previous $456 million the U.S. Government secure to J&J for vaccine development in March. That compares with the $19.50 per dose that the U.S. Is paying for the vaccine being developed by Pfizer INC (PFE.N) and German biotech BioNTech SE (22UAy.F).
J&J is finding out both one and two-dose regimens of its vaccine. Pfizer and BioNTech’s candidate would require 2 doses per person treated. The producer stated that it might deliver the vaccine to the biomedical Advanced analysis and Development Authority (BARDA) on a not-for-profit basis to be used once approval or emergency use authorization by the U.S. Food and Drug Administration (FDA).
The U.S. Government can also purchase an extra 200 million doses underneath a subsequent agreement. J&J did not disclose that deal’s worth.
The race for vaccines and treatments for the already infamous COVID-19 started, the U.S. has been signing deals already to buy them through its Operation Warp Speed program. All the other producers who have signed deals include Sanofi SA (SASY.PA) and Regeneron INC. REGN.N This is J&J’s 1st deal to provide its investigational vaccine to a country. Talks are underway with the European Union, however, no deal has yet been reached.
J&J’s investigational vaccine is presently being tested on healthy volunteers within the U.S. And Belgium in an early-stage study. There are presently no approved vaccines for COVID-19. Over twenty are in clinical trials.
